First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: Results of a prospective, randomized phase III study

First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: Results of a prospective, randomized phase III study

Bibliographic Details
Main Authors: Bergh, J., Bondarenko, I., Lichinitser, M., Liljegren, A., Greil, R., Voytko, N., Makhson, A., Cortes, J., Lortholary, A., Bischoff, J., Chan, Arlene, Delaloge, S., Huang, X., Kern, K., Giorgetti, C.
Format: Journal Article
Published: American Society of Clinical Oncology 2012
Online Access:http://hdl.handle.net/20.500.11937/17432

Internet

http://hdl.handle.net/20.500.11937/17432

Similar Items